## Tegeprotafib

®

MedChemExpress

Cat. No.: CAS No.:	HY-153446 2407610-46-0	-
Molecular Formula:	C <sub>13</sub> H <sub>11</sub> FN <sub>2</sub> O <sub>5</sub> S	0 E 0=9-NH
Molecular Weight:	326.3	
Target:	Phosphatase	
Pathway:	Metabolic Enzyme/Protease	ОН
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	

## SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.0647 mL	15.3233 mL	30.6466 mL
	5 mM	0.6129 mL	3.0647 mL	6.1293 mL
	10 mM	0.3065 mL	1.5323 mL	3.0647 mL

BIOLOGICAL ACTIV			
Description	Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC <sub>50</sub> s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively <sup>[1]</sup> .		
IC <sub>50</sub> & Target	IC50: 4.4 nM (PTPN2), 1-10 nM (PTP1B) <sup>[1]</sup>		
In Vitro	Tegeprotafib (Compound 124; 5 days) inhibits IFNγ (0.5 ng/mL) induced B16F10 cellular growth with a percent growth inhibition of 60-90% at 33 μM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Tegeprotafib (Compound 124; 300 mg/kg; oral; BID for 21 days) shows antitumor activity in mice <sup>[1]</sup> .         MCE has not independently confirmed the accuracy of these methods. They are for reference only.         Animal Model:       Female C57B1/6 mice, MC-38 tumor model <sup>[1]</sup> Dosage:       300 mg/kg/dose		



Administration:	Oral, twice a day (BID) at 7am and 5pm for 21 days
Result:	Within 7-10 days of treatment, apparent tumor stasis and shrinkage was observed. 50% of mice achieved complete cures, and an overall TGI <sub>MEX</sub> was 75%. The frequency of functional, granzyme B (GzB) producing cells within the cytotoxic CD8+ T population in the spleen was 2.9-fold increased over vehicle control treated animals. Increased IP10 levels plasma.

## REFERENCES

[1]. Elliot FARNEY, et al. Protein tyrosine phosphatase inhibitors and methods of use thereof. Patent WO2019246513A1.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA